Amneal reported positive interim results from its ongoing Phase 4 ELEVATE-PD switch study, presented at AAN 2026, showing that Crexont (carbidopa/levodopa extended-release) delivered clinically meaningful gains in motor control after six weeks across 111 Parkinson’s disease patients. Patients switching from immediate-release carbidopa/levodopa, immediate-release plus a COMT inhibitor, or Rytary experienced increases of roughly three additional hours of daily “good on” time and comparable reductions in “off” time. Mean MDS-UPDRS total scores improved by 10–15 points depending on prior therapy. Notably, among patients switching from Rytary, continuous “good on” intervals nearly doubled from 3.45 to 6.58 hours, alongside a reduction in daily motor fluctuations. Adverse events were generally mild to moderate and aligned with expectations; the most common were dizziness (9.0%), nausea (7.2%), falls (7.2%), dyskinesia (4.5%), hallucination (3.6%), and headache (3.6%).
Beyond a positive readout, the study functions as a strategic lever in a maturing oral levodopa market. Crexont’s formulation is designed for prolonged levodopa exposure via mucoadhesive technology, positioning it as a next-generation alternative to both generic immediate-release regimens and older extended-release options. For a company that also sells Rytary, switch data showing sustained improvements sets the stage for an orchestrated migration to a newer brand platform. The commercial question is whether Amneal can translate short-term motor gains into durable share capture and formulary elevation without eroding its existing franchise.
The timing matters. Parkinson’s prevalence is rising with aging populations, yet payers are tightening step-edits and scrutinizing incremental value. For patients and caregivers, longer, uninterrupted “good on” intervals can translate to less dosing complexity and greater functional independence, which has downstream implications for falls, caregiver burden, and productivity. For neurologists, a credible switch pathway with predictable conversion and manageable tolerability could streamline clinic workflows and reduce regimen tinkering. For payers, three additional hours of “good on” time sounds compelling; the bar, however, is demonstration that these gains persist over months, reduce healthcare utilization, and justify a premium relative to generic levodopa plus adjuncts. Amneal’s plan to release longer-term and patient-reported outcomes through 2026 is critical to converting clinical enthusiasm into contracted access.
This development also fits a broader industry pattern: real-world, open-label switch programs are increasingly central to launch execution in neurology, where comparative trials are scarce and payer evidence demands are steep. While device-aided and subcutaneous levodopa options are advancing for fluctuation-heavy patients, oral levodopa remains the backbone of PD care. The sponsor’s strategy appears to be to win earlier in the treatment continuum by offering longer-lasting plasma levels and longer continuous “good on” stretches, thereby preempting add-on polypharmacy or escalation to invasive therapies. Competitively, the data put pressure on adjunct approaches positioned mainly to extend “on” time and challenge the stickiness of older extended-release formulations as real-world performance gaps become visible.
What comes next will determine whether Crexont becomes the default oral levodopa in fluctuation management or a niche upgrade. Watch for durability of effect at 3–12 months without a dyskinesia penalty, adherence and persistence relative to prior regimens, clarity and simplicity of dose-conversion algorithms, and whether Medical Affairs can produce convincing PROs tied to caregiver time and fall risk. The decisive signal may be payer behavior: if plans move Crexont above older extended-release options and relax step therapy, the market could pivot quickly; if not, the brand will need to win share neurologist by neurologist through operationally tight switching playbooks.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
